Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy

H. J. Long, D. J. Schaid, A. J. Schutt, J. N. Ingle, C. L. Loprinzi, J. H. Edmonson

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

A total of 25 patients with metastatic breast cancer who had failed one prior chemotherapy regimen and had not received prior treatment with doxorubicin were treated with menogaril (200 mg/m2 i.v. over 1 h) every 4 weeks. Four patients (16%) achieved partial regressions lasting a median of 46 days. The median survival was 264 days. Seventeen patients subsequently received doxorubicin after removal from protocol and six (35%) achieved objective regression. We conclude that menogaril administered by the method that we employed has marginal activity in women with metastatic breast cancer after failure of prior chemotherapy. Failure to respond to menogaril does not preclude response to subsequent treatment with doxorubicin.

Original languageEnglish (US)
Pages (from-to)524-527
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number5
DOIs
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy'. Together they form a unique fingerprint.

  • Cite this